Antigen-specific TIL therapy for melanoma: A flexible platform for personalized cancer immunotherapy

European Journal of Immunology

Volumn 46, Issue 6, 2016, Pages 1351-1360

  Kelderman, Sander ^a   Heemskerk, Bianca ^a   Fanchi, Lorenzo ^a   Philips, Daisy ^a   Toebes, Mireille ^a   Kvistborg, Pia ^a   van Buuren, Marit M ^a   van Rooij, Nienke ^a   Michels, Samira ^a   Germeroth, Lothar ^b   Haanen, John B A G ^a   Schumacher, N M ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b Stage Cell Therapeutics   (Germany)

Author keywords

Antigens CD8+ T cells Enrichment Melanoma TIL therapy

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN;

ARTICLE; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL POPULATION; HUMAN; HUMAN CELL; MELANOMA; PERSONALIZED MEDICINE; PHENOTYPE; PRIORITY JOURNAL; TUMOR ASSOCIATED LEUKOCYTE;

EID: 84973646366     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201545849     Document Type: Article

References (39)

1. Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R. et al., Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 2011. 364: 2507–2516.
2. Shames, D. S. and Wistuba, II, The evolving genomic classification of lung cancer. J. Pathol. 2014. 232: 121–133.
3. Le Tourneau, C., Paoletti, X., Servant, N., Bieche, I., Gentien, D., Rio Frio, T., Vincent-Salomon, A. et al., Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trial. Br. J. Cancer 2014. 111: 17–24.
4. Rosenberg, S. A. and Restifo, N. P., Adoptive cell transfer as personalized immunotherapy for human cancer. Science 2015. 348: 62–68.
5. Radvanyi, L. G., Bernatchez, C., Zhang, M., Fox, P. S., Miller, P., Chacon, J., Wu, R. et al., Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin. Cancer Res. 2012. 18: 6758–6770.
6. Besser, M. J., Shapira-Frommer, R., Itzhaki, O., Treves, A. J., Zippel, D. B., Levy, D., Kubi, A. et al., Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies. Clin. Cancer Res. 2013. 19: 4792–4800.
7. Dudley, M. E., Gross, C. A., Somerville, R. P., Hong, Y., Schaub, N. P., Rosati, S. F., White, D. E. et al., Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma. J. Clin. Oncol. 2013. 31: 2152–2159.
8. Besser, M. J., Shapira-Frommer, R., Treves, A. J., Zippel, D., Itzhaki, O., Hershkovitz, L., Levy, D. et al., Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clin. Cancer Res. 2010. 16: 2646–2655.
9. Dudley, M. E., Gross, C. A., Langhan, M. M., Garcia, M. R., Sherry, R. M., Yang, J. C., Phan, G. Q. et al., CD8+ enriched "young" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma. Clin. Cancer Res. 2010. 16: 6122–6131.
10. Kvistborg, P., van Buuren, M. M. and Schumacher, T. N., Human cancer regression antigens. Curr. Opin. Immunol. 2013. 25: 284–290.
11. Alexandrov, L. B., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A., Behjati, S., Biankin, A. V., Bignell, G. R. et al., Signatures of mutational processes in human cancer. Nature 2013. 500: 415–421.
12. Schumacher, T. N. and Schreiber, R. D., Neoantigens in cancer immunotherapy. Science 2015. 348: 69–74.
13. van Rooij, N., van Buuren, M. M., Philips, D., Velds, A., Toebes, M., Heemskerk, B., van Dijk, L. J. et al., Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J. Clin. Oncol. 2013. 31: e439-442.
14. Robbins, P. F., Lu, Y. C., El-Gamil, M., Li, Y. F., Gross, C., Gartner, J., Lin, J. C. et al., Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat. Med. 2013. 19: 747–752.
15. Lu, Y. C., Yao, X., Crystal, J. S., Li, Y. F., El-Gamil, M., Gross, C., Davis, L. et al., Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions. Clin. Cancer Res. 2014. 20: 3401–3410.
16. Kvistborg, P., Shu, C. J., Heemskerk, B., Fankhauser, M., Thrue, C. A., Toebes, M., van Rooij, N. et al., TIL therapy broadens the tumor-reactive CD8(+) T cell compartment in melanoma patients. Oncoimmunology 2012. 1: 409–418.
17. Knabel, M., Franz, T. J., Schiemann, M., Wulf, A., Villmow, B., Schmidt, B., Bernhard, H. et al., Reversible MHC multimer staining for functional isolation of T-cell populations and effective adoptive transfer. Nat. Med. 2002. 8: 631–637.
18. Neudorfer, J., Schmidt, B., Huster, K. M., Anderl, F., Schiemann, M., Holzapfel, G., Schmidt, T. et al., Reversible HLA multimers (Streptamers) for the isolation of human cytotoxic T lymphocytes functionally active against tumor- and virus-derived antigens. J. Immunol. Methods 2007. 320: 119–131.
19. Toebes, M., Coccoris, M., Bins, A., Rodenko, B., Gomez, R., Nieuwkoop, N. J., van de Kasteele, W. et al., Design and use of conditional MHC class I ligands. Nat. Med. 2006. 12: 246–251.
20. Rodenko, B., Toebes, M., Hadrup, S. R., van Esch, W. J., Molenaar, A. M., Schumacher, T. N. and Ovaa, H., Generation of peptide-MHC class I complexes through UV-mediated ligand exchange. Nat. Protoc. 2006. 1: 1120–1132.
21. Schmitt, A., Tonn, T., Busch, D. H., Grigoleit, G. U., Einsele, H., Odendahl, M., Germeroth, L. et al., Adoptive transfer and selective reconstitution of streptamer-selected cytomegalovirus-specific CD8+ T cells leads to virus clearance in patients after allogeneic peripheral blood stem cell transplantation. Transfusion 2011. 51: 591–599.
22. Cobbold, M., Khan, N., Pourgheysari, B., Tauro, S., McDonald, D., Osman, H., Assenmacher, M. et al., Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J. Exp. Med. 2005. 202: 379–386.
23. Odendahl, M., Grigoleit, G. U., Bonig, H., Neuenhahn, M., Albrecht, J., Anderl, F., Germeroth, L. et al., Clinical-scale isolation of ‘minimally manipulated’ cytomegalovirus-specific donor lymphocytes for the treatment of refractory cytomegalovirus disease. Cytotherapy 2014. 16: 1245–1256.
24. Bouquie, R., Bonnin, A., Bernardeau, K., Khammari, A., Dreno, B., Jotereau, F., Labarriere, N. et al., A fast and efficient HLA multimer-based sorting procedure that induces little apoptosis to isolate clinical grade human tumor specific T lymphocytes. Cancer Immunol. Immunother. 2009. 58: 553–566.
25. Labarriere, N., Fortun, A., Bellec, A., Khammari, A., Dreno, B., Saiagh, S. and Lang, F., A full GMP process to select and amplify epitope-specific T lymphocytes for adoptive immunotherapy of metastatic melanoma. Clin. Dev. Immunol. 2013. 2013: 932318.
26. Hintzen, R. Q., de Jong, R., Lens, S. M., Brouwer, M., Baars, P. and van Lier, R. A., Regulation of CD27 expression on subsets of mature T-lymphocytes. J. Immunol. 1993. 151: 2426–2435.
27. Rosenberg, S. A., Yang, J. C., Sherry, R. M., Kammula, U. S., Hughes, M. S., Phan, G. Q., Citrin, D. E. et al., Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin. Cancer Res. 2011. 17: 4550–4557.
28. Rizvi, N. A. et al., Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer. Science 2015. 348: 124–128.
29. Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A. et al., Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 2014. 371: 2189–2199.
30. Gros, A., Robbins, P. F., Yao, X., Li, Y. F., Turcotte, S., Tran, E., Wunderlich, J. R. et al., PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors. J. Clin. Invest. 2014. 124: 2246–2259.
31. Ye, Q., Song, D. G., Poussin, M., Yamamoto, T., Best, A., Li, C., Coukos, G. et al., CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor. Clin. Cancer Res. 2014. 20: 44–55.
32. Wolfl, M., Kuball, J., Eyrich, M., Schlegel, P. G. and Greenberg, P. D., Use of CD137 to study the full repertoire of CD8+ T cells without the need to know epitope specificities. Cytometry A 2008. 73: 1043–1049.
33. Cohen, C. J., Gartner, J. J., Horovitz-Fried, M., Shamalov, K., Trebska-McGowan, K., Bliskovsky, V. V., Parkhurst, M. R. et al., Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes. J. Clin. Invest. 2015. 125: 3981–3991.
34. Larkin, J., Del Vecchio, M., Ascierto, P. A., Krajsova, I., Schachter, J., Neyns, B., Espinosa, E. et al., Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study. Lancet Oncol. 2014. 15: 436–444.
35. Lundegaard, C., Lamberth, K., Harndahl, M., Buus, S., Lund, O. and Nielsen, M., NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8–11. Nucleic Acids Res. 2008. 36: W509–W512.
36. Nielsen, M., Lundegaard, C., Worning, P., Hvid, C. S., Lamberth, K., Buus, S., Brunak, S. et al., Improved prediction of MHC class I and class II epitopes using a novel Gibbs sampling approach. Bioinformatics 2004. 20: 1388–1397.
37. Calis, J. J., Reinink, P., Keller, C., Kloetzel, P. M. and Kesmir, C., Role of peptide processing predictions in T cell epitope identification: contribution of different prediction programs. Immunogenetics 2015. 67: 85–93.
38. Toebes, M., Rodenko, B., Ovaa, H. and Schumacher, T. N., Generation of peptide MHC class I monomers and multimers through ligand exchange. Curr. Protoc. Immunol. 2009. Chapter 18: Unit 18 16.
39. Kvistborg, P., Philips, D., Kelderman, S., Hageman, L., Ottensmeier, C., Joseph-Pietras, D., Welters, M. J. et al., Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response. Sci. Transl. Med. 2014. 6: 254ra128.